What to Know About the USPTO’s Duty of Candor Guidance Regarding FDA Submissions
Fish & Richardson Trademark & Copyright Thoughts
SEPTEMBER 16, 2022
In view of this notice, life sciences companies should consider involving patent counsel in the review of relevant FDA submissions for possible inconsistencies with PTO filings and determination of the appropriate course of action where material inconsistencies are found to exist. Preserving confidentiality and privilege.
76 
Let's personalize your content